Driving the viral vector expressway: speeding through AAV manufacturing

نویسندگان

چکیده

Watch this FastFacts to discover:     How the VirusExpress® 293 AAV Production Platform can help speed your gene therapy patients  high-through put screening has enhanced efficiency of platform     How improvements transfection and cell culture media impact performance   our platform performs with GFP model virus in serotypes AAV2, AAV5, AAV6, a customer’s GOI AAV9.Andi Ushijima is Scientist Viral Vector Innovation Technology group at MilliporeSigma. She variety upstream bioprocessing experience working on bioreactor development scale up monoclonal antibodies, virus-like particles, viral vectors. received her BSc Bioengineering UCSD.Henry worked since 1981 both biotechnology pharmaceutical sectors, developing protein expression systems bacterial, insect mammalian hosts. He joined MilliporeSigma 2001 as an R&D manager, currently leads Producer Cell Lines group.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Progress and challenges in viral vector manufacturing.

Promising results in several clinical studies have emphasized the potential of gene therapy to address important medical needs and initiated a surge of investments in drug development and commercialization. This enthusiasm is driven by positive data in clinical trials including gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Amaurosis Type 2 and ...

متن کامل

Muscling through AAV immunity.

AAV-1 is one of the most promising vectors for gene delivery to skeletal muscle. In this issue of Blood, Mingozzi and colleagues now demonstrate that AAV-1-mediated gene transfer into human skeletal muscle results in activation of capsid-specific T cells.

متن کامل

Gene therapy for choroideremia using an adeno-associated viral (AAV) vector.

Choroideremia is an outer retinal degeneration with a characteristic clinical appearance that was first described in the nineteenth century. The disorder begins with reduction of night vision and gradually progresses to blindness by middle age. The appearance of the fundus in sufferers is recognizable by the characteristic pale color caused by the loss of the outer retina, retinal-pigmented epi...

متن کامل

Developing an Adeno-Associated Viral Vector (AAV) Toolbox for CNS Gene Therapy: A Dissertation

Neurological disorders – disorders of the brain, spine and associated nerves – are a leading contributor to global disease burden with a sizable economic cost. Adeno-associated viral (AAV) vectors have emerged as an effective platform for CNS gene therapy and have shown early promise in clinical trials. These trials involve direct infusion into brain parenchyma, an approach that may be suboptim...

متن کامل

The AAV vector toolkit: poised at the clinical crossroads.

The discovery of naturally occurring adeno-associated virus (AAV) isolates in different animal species and the generation of engineered AAV strains using molecular genetics tools have yielded a versatile AAV vector toolkit. Promising results in preclinical animal models of human disease spurred the much awaited transition toward clinical application, and early successes in phase I/II clinical t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cell & gene therapy insights

سال: 2022

ISSN: ['2059-7800', '2397-0545']

DOI: https://doi.org/10.18609/cgti.2022.198